Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy

被引:17
作者
Agoston, Agoston T. [1 ]
Zheng, Yifan [1 ]
Bueno, Raphael [1 ]
Lauwers, Gregory Y. [2 ]
Odze, Robert D. [1 ]
Srivastava, Amitabh [1 ]
机构
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
关键词
esophagus; adenocarcinoma; neoadjuvant therapy; remission; survival; prognosis; SIGNET-RING CELL; PATHOLOGICAL COMPLETE RESPONSE; LONG-TERM OUTCOMES; PREOPERATIVE CHEMORADIATION; GASTROESOPHAGEAL JUNCTION; ESOPHAGOGASTRIC JUNCTION; PROGNOSTIC-SIGNIFICANCE; ENDOSCOPIC ULTRASOUND; CANCER; CHEMORADIOTHERAPY;
D O I
10.1097/PAS.0000000000000420
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Complete response to neoadjuvant therapy, determined by pathologic examination of the resection specimen (pCR), is associated with a favorable outcome in esophageal adenocarcinomas (EAC), but there is significant heterogeneity in survival reported within this group. Our aim was to determine predictors of disease recurrence (DR) and survival in EAC patients with pCR to neoadjuvant therapy. A total of 93 EAC patients with pCR to neoadjuvant therapy were identified, and a predetermined set of clinicopathologic variables was examined, including patient age, sex, tumor location, pretreatment tumor size, endoscopic ultrasound T and N stage, histologic tumor type, and grade in pretreatment biopsies. The esophagectomy specimens were evaluated for the extent of sampling of the tumor bed, depth of treatment-related changes, presence of treatment effect in lymph nodes, and the total number of lymph nodes examined. Complete histologic examination of the tumor bed was the most significant predictor of favorable outcome for both DR (hazard ratio [HR]=0.42; 95% confidence interval [CI]: 0.21-0.82; P=0.011) and disease-specific mortality (HR=0.40; 95% CI: 0.22-0.70; P<0.01). The presence of a high-grade adenocarcinoma component in pretreatment biopsies (HR=2.19; 95% CI: 1.22-3.94; P<0.01) was associated with a higher disease-specific mortality, and involvement of the gastroesophageal junction (HR=2.37; 95% CI: 1.11-5.06; P=0.026) was associated with a higher rate of DR. Heterogeneity in outcomes for EAC patients with pCR to therapy can be explained by adequacy of histologic examination of the tumor bed, high tumor grade, and involvement of the gastroesophageal junction.
引用
收藏
页码:1085 / 1092
页数:8
相关论文
共 39 条
[1]   ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients [J].
Ajani, J. A. ;
Wang, X. ;
Song, S. ;
Suzuki, A. ;
Taketa, T. ;
Sudo, K. ;
Wadhwa, R. ;
Hofstetter, W. L. ;
Komaki, R. ;
Maru, D. M. ;
Lee, J. H. ;
Bhutani, M. S. ;
Weston, B. ;
Baladandayuthapani, V. ;
Yao, Y. ;
Honjo, S. ;
Scott, A. W. ;
Skinner, H. D. ;
Johnson, R. L. ;
Berry, D. .
MOLECULAR ONCOLOGY, 2014, 8 (01) :142-149
[2]   Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer [J].
Ajani, J. A. ;
Correa, A. M. ;
Hofstetter, W. L. ;
Rice, D. C. ;
Blum, M. A. ;
Suzuki, A. ;
Taketa, T. ;
Welsh, J. ;
Lin, S. H. ;
Lee, J. H. ;
Bhutani, M. S. ;
Ross, W. A. ;
Maru, D. M. ;
Macapinlac, H. A. ;
Erasmus, J. ;
Komaki, R. ;
Mehran, R. J. ;
Vaporciyan, A. A. ;
Swisher, S. G. .
ANNALS OF ONCOLOGY, 2012, 23 (10) :2638-2642
[3]  
[Anonymous], J THORAC CARDIOVASC
[4]  
[Anonymous], 2010, WHO CLASSIFICATION T
[5]  
Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
[6]   Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival [J].
Berger, AC ;
Farma, J ;
Scott, WJ ;
Freedman, G ;
Weiner, L ;
Cheng, JD ;
Wang, H ;
Goldberg, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4330-4337
[7]   Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort [J].
Cheedella, N. K. S. ;
Suzuki, A. ;
Xiao, L. ;
Hofstetter, W. L. ;
Maru, D. M. ;
Taketa, T. ;
Sudo, K. ;
Blum, M. A. ;
Lin, S. H. ;
Welch, J. ;
Lee, J. H. ;
Bhutani, M. S. ;
Rice, D. C. ;
Vaporciyan, A. A. ;
Swisher, S. G. ;
Ajani, J. A. .
ANNALS OF ONCOLOGY, 2013, 24 (05) :1262-1266
[8]   Long-term outcomes and prognostic factors for patients with esophageal cancer following radiotherapy [J].
Chen, Chuang-Zhen ;
Chen, Jian-Zhou ;
Li, De-Rui ;
Lin, Zhi-Xiong ;
Zhou, Ming-Zhen ;
Li, Dong-Sheng ;
Chen, Zhi-Jian .
WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (10) :1639-1644
[9]   Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma [J].
Chirieac, LR ;
Swisher, SG ;
Correa, AM ;
Ajani, JA ;
Komaki, RR ;
Rashid, A ;
Hamilton, SR ;
Wu, TT .
CLINICAL CANCER RESEARCH, 2005, 11 (06) :2229-2236
[10]   Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival [J].
Donahue, James M. ;
Nichols, Francis C. ;
Li, Zhuo ;
Schomas, David A. ;
Allen, Mark S. ;
Cassivi, Stephen D. ;
Jatoi, Aminah ;
Miller, Robert C. ;
Wigle, Dennis A. ;
Shen, K. Robert ;
Deschamps, Claude .
ANNALS OF THORACIC SURGERY, 2009, 87 (02) :392-399